Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity

Cited by papers we hold 2

• PROTACs: great opportunities for academia and industry (an update from 2020 to 2021) · 2022
  No notice
• Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.